<DOC>
	<DOCNO>NCT00652223</DOCNO>
	<brief_summary>The purpose study test safety , tolerability , immunogenicity clinical efficacy combination treatment AllQbG10 patient rhino-conjunctivitis asthma due house dust mite allergy single-center , open-label setting .</brief_summary>
	<brief_title>Effect Allergen Vaccine Patients With Allergic Rhino-Conjunctivitis Asthma Due House Dust Mite Allergy</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<criteria>Mild moderate perennial allergic rhinoconjunctivitis due sensitization house dust mites Mild asthma Females nonreproductive agree practice effective accept method contraception Relevant cardiovascular , renal , pulmonary endocrine disease History autoimmune disease Severe allergies History active infectious disease Current diagnosis history malignancy Relevant neurological psychiatric disorder Pregnancy lactation History alcohol abuse recreational drug Use investigational drug within three month enrolment Blood donation within 30 day enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>